Cargando…

Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis

BACKGROUND AND PURPOSE: Anti-titin antibodies are antistriational antibodies associated with thymoma-associated myasthenia gravis (MG). We evaluated whether the patients with anti-titin antibody are more frequently hospitalized to manage thymoma-associated MG than those patients without anti-titin a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ki Hoon, Kim, Seung Woo, Cho, Jinhyuk, Chung, Hye Yoon, Shin, Ha Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581133/
https://www.ncbi.nlm.nih.gov/pubmed/36277908
http://dx.doi.org/10.3389/fneur.2022.978997
_version_ 1784812548904714240
author Kim, Ki Hoon
Kim, Seung Woo
Cho, Jinhyuk
Chung, Hye Yoon
Shin, Ha Young
author_facet Kim, Ki Hoon
Kim, Seung Woo
Cho, Jinhyuk
Chung, Hye Yoon
Shin, Ha Young
author_sort Kim, Ki Hoon
collection PubMed
description BACKGROUND AND PURPOSE: Anti-titin antibodies are antistriational antibodies associated with thymoma-associated myasthenia gravis (MG). We evaluated whether the patients with anti-titin antibody are more frequently hospitalized to manage thymoma-associated MG than those patients without anti-titin antibody. METHODS: Patients with thymoma-associated MG who conducted the serological test for anti-titin antibody were retrospectively included. Disease severity, treatments, MG-related annual hospitalization rate, and MG-related emergency room (ER) visit rate were compared between the patients with anti-titin antibody and those patients without anti-titin antibody. Multivariate analysis was conducted to analyze the association between anti-titin antibody serostatus and multiple admissions (hospitalization or ER visit of ≥2 times). RESULTS: Of the 64 included patients, 31 (48.4%) patients were positive for anti-titin antibody (titin+ group) and 33 (51.6%) patients were negative for anti-titin antibody (titin– group). Both the annual rate of MG-related hospitalization and ER visit were significantly higher in the titin+ group [0.2 (0.1–0.6) and 0.1 (0–0.2) per year, respectively] than those in the titin– group [0 (0–0.2) and 0 (0–0) per year, p = 0.004 and p = 0.006, respectively]. In multivariate analysis, positive anti-titin antibody was still significantly associated with multiple admissions [odds ratio (OR) 4.11, 95% CI 1.05–16.03] compared to the titin– group as a reference after adjusting for sex, follow-up duration, age at onset, systemic chemotherapy, and the Masaoka staging. CONCLUSION: The presence of anti-titin antibody is associated with more frequent hospital utilization. Personalized explanation and careful monitoring strategy could be required in patients with thymoma-associated MG with anti-titin antibody for the timely detection of relapses.
format Online
Article
Text
id pubmed-9581133
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95811332022-10-20 Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis Kim, Ki Hoon Kim, Seung Woo Cho, Jinhyuk Chung, Hye Yoon Shin, Ha Young Front Neurol Neurology BACKGROUND AND PURPOSE: Anti-titin antibodies are antistriational antibodies associated with thymoma-associated myasthenia gravis (MG). We evaluated whether the patients with anti-titin antibody are more frequently hospitalized to manage thymoma-associated MG than those patients without anti-titin antibody. METHODS: Patients with thymoma-associated MG who conducted the serological test for anti-titin antibody were retrospectively included. Disease severity, treatments, MG-related annual hospitalization rate, and MG-related emergency room (ER) visit rate were compared between the patients with anti-titin antibody and those patients without anti-titin antibody. Multivariate analysis was conducted to analyze the association between anti-titin antibody serostatus and multiple admissions (hospitalization or ER visit of ≥2 times). RESULTS: Of the 64 included patients, 31 (48.4%) patients were positive for anti-titin antibody (titin+ group) and 33 (51.6%) patients were negative for anti-titin antibody (titin– group). Both the annual rate of MG-related hospitalization and ER visit were significantly higher in the titin+ group [0.2 (0.1–0.6) and 0.1 (0–0.2) per year, respectively] than those in the titin– group [0 (0–0.2) and 0 (0–0) per year, p = 0.004 and p = 0.006, respectively]. In multivariate analysis, positive anti-titin antibody was still significantly associated with multiple admissions [odds ratio (OR) 4.11, 95% CI 1.05–16.03] compared to the titin– group as a reference after adjusting for sex, follow-up duration, age at onset, systemic chemotherapy, and the Masaoka staging. CONCLUSION: The presence of anti-titin antibody is associated with more frequent hospital utilization. Personalized explanation and careful monitoring strategy could be required in patients with thymoma-associated MG with anti-titin antibody for the timely detection of relapses. Frontiers Media S.A. 2022-10-05 /pmc/articles/PMC9581133/ /pubmed/36277908 http://dx.doi.org/10.3389/fneur.2022.978997 Text en Copyright © 2022 Kim, Kim, Cho, Chung and Shin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Kim, Ki Hoon
Kim, Seung Woo
Cho, Jinhyuk
Chung, Hye Yoon
Shin, Ha Young
Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis
title Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis
title_full Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis
title_fullStr Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis
title_full_unstemmed Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis
title_short Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis
title_sort anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581133/
https://www.ncbi.nlm.nih.gov/pubmed/36277908
http://dx.doi.org/10.3389/fneur.2022.978997
work_keys_str_mv AT kimkihoon antititinantibodyisassociatedwithmorefrequenthospitalizationtomanagethymomaassociatedmyastheniagravis
AT kimseungwoo antititinantibodyisassociatedwithmorefrequenthospitalizationtomanagethymomaassociatedmyastheniagravis
AT chojinhyuk antititinantibodyisassociatedwithmorefrequenthospitalizationtomanagethymomaassociatedmyastheniagravis
AT chunghyeyoon antititinantibodyisassociatedwithmorefrequenthospitalizationtomanagethymomaassociatedmyastheniagravis
AT shinhayoung antititinantibodyisassociatedwithmorefrequenthospitalizationtomanagethymomaassociatedmyastheniagravis